Digital intelligence specialist Cellebrite DI Ltd. (Nasdaq: CLBT) is jumping on Thursday, November 13, 2025, after posting stronger‑than‑expected third‑quarter results and lifting its 2025 outlook, prompting multiple bullish calls from Wall Street.
CLBT stock jumps as investors digest Q3 beat
Cellebrite shares are rallying sharply in today’s session. As of mid‑afternoon trading on November 13, CLBT is changing hands around $19.80, up roughly 24% from the pre‑earnings close, on heavy volume. 1
Pre‑market, the stock was already up more than 20%, after the company reported better‑than‑expected Q3 2025 numbers and raised its full‑year guidance, drawing trader attention to the name. 1
Inside Cellebrite’s Q3 2025 results
Cellebrite’s fiscal third quarter ended September 30, 2025, and the company’s official release paints the picture of a software business still growing at a healthy clip.
Headline numbers
- Total revenue:$126.0 million, up 18% year‑over‑year 2
- Annual recurring revenue (ARR):$439.8 million, up 19% YoY 2
- GAAP net income:$20.2 million 2
- Non‑GAAP net income:$36.9 million; adjusted EBITDA:$37.7 million, for a 29.9% margin 2
- Non‑GAAP EPS: about $0.14, ahead of consensus, delivering positive earnings surprise according to several data providers 3
A Reuters‑syndicated note highlighted that the 18% revenue growth beat analyst estimates, with adjusted EBITDA also coming in ahead of expectations. Net income was slightly below some forecasts but remained firmly positive. 4
Revenue mix favors recurring subscriptions
From the detailed financials, the business mix continues to tilt toward recurring software: 5
- Subscription services revenue: ~$84.2M vs. ~$69.3M a year ago (about 21% growth)
- Term‑license revenue: ~$28.5M vs. ~$24.0M (high‑teens growth)
- Professional services: declined modestly, reflecting the ongoing shift toward scalable, software‑driven deployments
That tilt toward subscriptions and cloud is important because it underpins the company’s rising ARR base and high gross margins (nearly 84%, per recent analyst commentary). 6
Overall, the quarter showed:
- Solid double‑digit top‑line growth
- Expanding high‑margin recurring revenue
- Strong profitability metrics for a mid‑cap software name
Guidance raised for Q4 and full‑year 2025
The other big driver behind today’s rally is upbeat guidance.
According to Cellebrite’s guidance update and summarized IR materials: 7
- Q4 2025 outlook
- Revenue:$123–$128 million (13–17% YoY growth)
- Adjusted EBITDA:$35–$38 million, implying 28–30% margin
- Full‑year 2025 outlook (raised)
- Revenue:$470–$475 million (roughly 17–18% YoY growth)
- ARR:$460–$475 million
- Adjusted EBITDA:$124–$127 million (around 26–27% margin)
- Free cash flow margin: around 30%
Notably, management has emphasized that these figures do not yet include any contribution from the pending acquisition of mobile‑virtualization specialist Corellium. 8
That “ex‑Corellium” guidance gives investors a cleaner view of the core business, while leaving potential upside once integration kicks in.
Wall Street reaction: Buy ratings and higher price targets
With the numbers out, the analyst community wasted little time re‑marking their models.
- Needham: Analyst Mike Cikos reiterated a Buy rating and raised his price target from $22 to $24, a roughly 9% bump that implies meaningful upside from pre‑earnings levels. 9
- Bank of America Securities: Analyst Tomer Zilberman reiterated a Buy rating with a $25 price target in a report today, pointing to improving demand from U.S. federal customers, expected budget flows, and FedRAMP‑certified cloud offerings as key growth drivers. 10
TipRanks and Reuters data show: 6
- A consensus Buy / Outperform rating from Street analysts
- A median 12‑month price target around $23, roughly 30–32% above Cellebrite’s pre‑earnings close
- An average forward P/E near 30×, in line with or slightly above software peers, reflecting expectations for sustained growth and high margins
A Finimize brief summed up the mood: Q3’s 18% revenue jump, strong adjusted EBITDA and upbeat guidance “impressed Wall Street,” with analysts lifting price targets as confidence strengthened around demand from U.S. agencies and international markets such as Latin America. 6
Strategic backdrop: AI, cloud and the Corellium deal
Behind the quarterly numbers sits a broader story about AI‑driven digital investigations, cloud‑first delivery and device virtualization.
AI at the heart of Cellebrite’s platform
A recent deep‑dive from digital forensics outlet Forensic Focus describes how Cellebrite is layering increasingly sophisticated AI into its tools to help investigators make sense of massive data sets—think phones, laptops, cloud accounts and messaging apps. 11
Examples of capabilities already available or in development include:
- Media and text classification, topic detection and entity extraction
- Speech‑to‑text and audio classification (e.g., distinguishing normal speech from shouting or crying)
- Agentic AI “assistants” that can follow investigative instructions and surface relevant evidence
- Conversational evidence querying, where investigators can ask natural‑language questions across datasets
- Synthetic media (deepfake) detection
These features aim to cut the time to surface key leads, reduce manual workload and help agencies tackle complex caseloads—from child exploitation to organized crime and IP theft. 11
Autumn 2025 Release and device virtualization
On the product side, Cellebrite’s Autumn 2025 Release introduced innovations across agentic AI, cloud and device virtualization, including deeper integration of Corellium technology for virtualized mobile devices. 12
The company has also teased Guardian Investigate, a new cloud‑native investigation environment that is currently in limited testing with design partners and slated for general availability in early 2026. 13
Corellium acquisition: expanding the TAM
Earlier this year, Cellebrite announced a deal to acquire Corellium, a leader in ARM‑based virtualization software, for an enterprise value of $170 million in cash plus $20 million in equity, with up to $30 million in performance‑based earn‑outs. 14
Corellium’s technology lets security teams and investigators interact with virtual replicas of mobile devices—useful for:
- Vulnerability research and malware analysis
- Mobile app and IoT security testing
- Digital investigations in both public and private sectors
With Corellium’s founder set to join Cellebrite as CTO, the deal is expected to broaden Cellebrite’s total addressable market across public safety, defense, intelligence and enterprise DevSecOps once fully approved and integrated. 14
What today’s news means for Cellebrite
Putting it all together, today’s move in CLBT reflects more than just a one‑off beat:
- Execution: Q3 showed that Cellebrite can still grow revenue in the high teens while maintaining robust profitability.
- Visibility: ARR nearing $440 million and a rising mix of subscription revenue give better line of sight into future cash flows. 2
- Optionality: The upcoming Autumn 2025 features, AI roadmap and Corellium integration offer potential upside not yet fully baked into current 2025 guidance. 12
- External validation: Banks like Needham and Bank of America reaffirming Buy ratings—and raising price targets—signal growing institutional confidence in the story. 9
Investors will now watch:
- Q4 performance – whether Cellebrite can deliver on its higher revenue and EBITDA targets in what is usually a seasonally softer quarter. 7
- Federal and international demand – especially in U.S. federal agencies and emerging markets like Latin America, which recent commentary highlighted as strong drivers. 10
- Corellium deal closure and integration – including regulatory approvals and evidence of cross‑sell or new use cases in enterprise security. 14
- AI product adoption – how quickly customers adopt new AI‑powered workflows such as agentic AI and conversational evidence search. 11
Important note
This article is for information and news purposes only and does not constitute financial or investment advice. Always do your own research or consult a licensed financial adviser before making investment decisions.
